N4P N4 Pharma Plc

N4 Pharma plc

 ("N4 Pharma" or the "Company")

N4 Pharma Webinar on SRI Collaboration

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, will provide a pre-recorded webinar relating to the Company's recent Collaboration Agreement with SRI International Inc. which was announced on 25 April 2024.

The webinar will be available for viewing on 7 May 2024 at 10:00 BST, via the Company's Investor Hub: investors.n4pharma.com/welcome.

Investors will be notified via email of the presentation if they have signed up to the N4 Pharma Investor Hub in advance, which can be done here: investors.n4pharma.com/auth/signup.

Investors are invited to submit questions in advance via N4 Pharma's Investor Hub, and CEO Nigel Theobald will address as many as possible. Register and submit questions at: investors.n4pharma.com

For more information please contact:

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.